251 related articles for article (PubMed ID: 32702302)
1. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.
Ouldali N; Varon E; Levy C; Angoulvant F; Georges S; Ploy MC; Kempf M; Cremniter J; Cohen R; Bruhl DL; Danis K
Lancet Infect Dis; 2021 Jan; 21(1):137-147. PubMed ID: 32702302
[TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
[TBL] [Abstract][Full Text] [Related]
3. Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey.
Ouldali N; Levy C; Varon E; Bonacorsi S; Béchet S; Cohen R; Angoulvant F;
Lancet Infect Dis; 2018 Sep; 18(9):983-991. PubMed ID: 30049623
[TBL] [Abstract][Full Text] [Related]
4. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
5. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
6. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
[TBL] [Abstract][Full Text] [Related]
7. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies.
Bar-Zeev N; Swarthout TD; Everett DB; Alaerts M; Msefula J; Brown C; Bilima S; Mallewa J; King C; von Gottberg A; Verani JR; Whitney CG; Mwansambo C; Gordon SB; Cunliffe NA; French N; Heyderman RS;
Lancet Glob Health; 2021 Jul; 9(7):e989-e998. PubMed ID: 34143997
[TBL] [Abstract][Full Text] [Related]
8. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN
Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905
[TBL] [Abstract][Full Text] [Related]
9. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
10. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
[TBL] [Abstract][Full Text] [Related]
11. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
Wijayasri S; Hillier K; Lim GH; Harris TM; Wilson SE; Deeks SL
PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
[TBL] [Abstract][Full Text] [Related]
12. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
13. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study.
Mackenzie GA; Hill PC; Jeffries DJ; Hossain I; Uchendu U; Ameh D; Ndiaye M; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Muhammad BS; Fombah AE; Saha D; Plumb I; Akano A; Ebruke B; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UNA; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2016 Jun; 16(6):703-711. PubMed ID: 26897105
[TBL] [Abstract][Full Text] [Related]
14. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
[TBL] [Abstract][Full Text] [Related]
15. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
Savulescu C; Krizova P; Lepoutre A; Mereckiene J; Vestrheim DF; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Varon E; Cotter S; Winje BA; Munoz-Almagro C; Garcia L; Castilla J; Smith A; Henriques-Normark B; Celentano LP; Hanquet G;
Lancet Respir Med; 2017 Aug; 5(8):648-656. PubMed ID: 28359798
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
[TBL] [Abstract][Full Text] [Related]
17. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.
van der Linden M; Falkenhorst G; Perniciaro S; Imöhl M
PLoS One; 2015; 10(7):e0131494. PubMed ID: 26132078
[TBL] [Abstract][Full Text] [Related]
18. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
19. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.
van der Linden M; Weiß S; Falkenhorst G; Siedler A; Imöhl M; von Kries R
Vaccine; 2012 Aug; 30(40):5880-5. PubMed ID: 22771186
[TBL] [Abstract][Full Text] [Related]
20. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
Mokaddas E; Albert MJ
Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
